WILLIAM WONG to Canada
This is a "connection" page, showing publications WILLIAM WONG has written about Canada.
Connection Strength
1.920
-
Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development. JMIR Public Health Surveill. 2025 Aug 20; 11:e66309.
Score: 0.225
-
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025 Jul; 43(7):765-778.
Score: 0.219
-
CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis. Med Decis Making. 2024 04; 44(3):296-306.
Score: 0.203
-
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology. 2024 08 01; 80(2):440-450.
Score: 0.203
-
A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada. Sci Rep. 2023 08 18; 13(1):13484.
Score: 0.195
-
Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in?a Publicly Funded Health System. Value Health. 2022 02; 25(2):247-256.
Score: 0.171
-
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist. 2020 03; 25(3):e512-e519.
Score: 0.151
-
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat. 2015 Jun; 151(3):639-52.
Score: 0.110
-
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Feb 17; 187(3):E110-E121.
Score: 0.108
-
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol. 2013 Mar; 27(3):137-47.
Score: 0.095
-
Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada. Leuk Lymphoma. 2025 Oct; 66(10):1875-1883.
Score: 0.055
-
Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023 Mar; 29(2):488-497.
Score: 0.047
-
The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver Int. 2020 06; 40(6):1282-1291.
Score: 0.039
-
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int. 2020 01; 40(1):51-59.
Score: 0.037
-
Cost Effectiveness of Hepatocellular Carcinoma Surveillance?After a Sustained Virologic Response to Therapy?in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1840-1849.e16.
Score: 0.035
-
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015 Feb; 150(1):169-80.
Score: 0.027